InvestorsHub Logo
icon url

rosemountbomber

08/31/20 4:47 AM

#293887 RE: Chemist2 #293883

Hi Chemist. I agree with your take. The data shows a stop to the progression and basically a 16% delta between V arm and placebo.

Now since V reduced total plaque by 9% and all the other types except for calcified by much more, it must mean that calcified plaque is a significant portion of the total plaque in the body. But stopping progression of calcified plaque along with regression of LAP is a very good thing. Vit K2 might be important in controlling calcium in blood vessels and might make a good addition.
icon url

sts66

08/31/20 5:31 PM

#294074 RE: Chemist2 #293883

Yeah, guess I agree that V at least stopped calcified plaque progression - but if you look at Table 2 (sorry for formatting) my lack of stats knowledge shows up - I see baseline and followup unadjusted number are 3.6 for both, which I inferred meant "does nothing", or "doesn't reduce" - the SD adjustment is where I lose track of how 3.6/3.6 can lead to -1%, and I ignored the growth in the placebo group of +15%. Adjusted p was 0.053 too, technically non-stat sig - and it's adjusted for what, the SD?


Table 2 Plaque changes by treatment group Treatment group
Baseline Follow-up Difference GLM modelling
Plaque type Mean (SD)
a
Mean (SD)
a
Mean (SD)
a
Unadj. P Adj. P %chg
Calci?cation IPE 3.6 (2.0) 3.6 (1.9) 0.0 (0.5) 0.0464 0.0531 -1%
Placebo 2.9 (1.9) 3.3 (2.1) 0.4 (1.2) 15%